Welcome to our dedicated page for Aspen Aerogels SEC filings (Ticker: ASPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspen Aerogels, Inc. (NYSE: ASPN) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8‑K, annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and other materials that describe Aspen’s financial condition, risk factors, governance, and key business developments.
For Aspen, which describes itself as a technology leader in sustainability, electrification solutions, and thermal management, Form 10‑K and 10‑Q filings are central sources for understanding segment performance in its Energy Industrial and Thermal Barrier businesses, the role of products such as PyroThin, Cryogel, and Pyrogel, and the company’s exposure to EV and energy infrastructure markets. These reports also reference non‑GAAP measures like Adjusted EBITDA, along with reconciliations to GAAP metrics.
Recent Form 8‑K filings have documented material events such as amendments to Aspen’s Credit, Security and Guaranty Agreement with MidCap Financial, including changes to minimum liquidity covenants, removal of a minimum EBITDA maintenance covenant, and clarifications on mandatory prepayments and acquisition baskets. Other 8‑K filings describe quarterly earnings announcements, financial outlook updates, and executive employment agreements, such as the promotion of an internal successor to Chief Financial Officer and Treasurer.
On Stock Titan, AI‑powered tools can help interpret these filings by summarizing lengthy sections, highlighting covenant changes, and explaining the implications of items like restructuring charges, liquidity thresholds, or executive compensation terms. Users can quickly locate 10‑K and 10‑Q reports for detailed financial data, review Form 4 insider transaction filings when available, and track how Aspen’s disclosures evolve over time in response to conditions in EV and energy infrastructure markets.
This page is a practical starting point for investors, analysts, and researchers who want a structured view of Aspen Aerogels’ regulatory history and the key contractual and governance information disclosed through its SEC filings.
Aspen Aerogels President and CEO Donald R. Young reported equity compensation grants and related tax withholding transactions. On March 4, he acquired 156,716 shares of Common Stock and 212,249 stock options at a grant price of $0.00 per share through awards.
The restricted stock units vest in three equal installments on March 4, 2027, March 4, 2028, and March 4, 2029, and the options follow the same one-third annual vesting schedule. On March 5, 8,618 shares of Common Stock at $3.27 per share were withheld by the company to cover minimum statutory taxes on RSU vesting, leaving him with 642,109 directly held shares, including 430,387 shares of Common Stock and 211,722 RSUs.
Aspen Aerogels senior vice president Gregg Landes reported equity compensation awards and related tax withholding transactions. On March 4, 2026, he received 57,462 restricted stock units and 77,824 stock options that each vest in three equal annual installments on March 4, 2027, 2028 and 2029. On March 5, 3,814 shares of common stock at $3.27 per share were withheld to cover minimum statutory taxes on RSU vesting. After these movements, he directly holds 22,735 shares of common stock, 82,120 RSUs and 77,824 stock options.
DEEGAN GLENN E. reported acquisition or exercise transactions in this Form 4 filing.
Aspen Aerogels chief accounting officer and general counsel Glenn E. Deegan received new equity awards. On March 4, 2026, he was granted 75,171 stock options and 55,503 restricted stock units (RSUs) at no cash cost.
Each RSU represents one share of common stock when it vests. Both the RSUs and options vest in three equal installments on March 4, 2027, March 4, 2028 and March 4, 2029, aligning compensation with longer-term company performance.
Aspen Aerogels SVP Corby C. Whitaker reported equity compensation changes and related tax withholding. On March 4, 2026, he acquired 57,462 shares of Common Stock as a grant and 77,824 stock options, both at a stated price of $0.0000 per share.
The options vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029. Related RSUs follow the same vesting schedule. On March 5, 2026, 3,907 shares of Common Stock were disposed of at $3.27 per share to cover minimum statutory tax withholding on RSU vesting, leaving 207,239 Common shares held directly.
Aspen Aerogels Inc. Chief Accounting Officer P. Daniel Santhosh reported a small share disposal related to taxes rather than an open‑market sale. On the vesting of Restricted Stock Units (RSUs), 986 shares of common stock were withheld by the company at $3.27 per share to satisfy minimum statutory tax withholding requirements.
After this tax-withholding disposition, Santhosh’s holdings total 15,330 equity interests, consisting of 5,593 shares of common stock and 9,737 RSUs. This type of transaction is routine for executives when RSUs vest and does not reflect a discretionary buy or sell decision.
Aspen Aerogels CFO & Treasurer Grant Douglas Thoele reported new equity awards and a small tax-related share disposition. On March 4, 2026, he received 55,298 shares of Common Stock as a grant and 74,893 stock options with a right to buy additional shares at an exercise price of $0.0000 per share. The options and related Restricted Stock Units (RSUs) vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029. On March 5, 2026, 2,368 shares of Common Stock were disposed of at $3.27 per share to satisfy minimum statutory tax withholding on RSU vesting. After these transactions, he directly owned 78,322 shares of Common Stock, which the footnotes state includes 9,014 shares and 69,308 RSUs.
Aspen Aerogels reported a sharp downturn in 2025 results and launched a strategic review. Fourth-quarter 2025 revenue was $41.3 million, down from $123.1 million a year earlier, with thermal barrier and energy industrial segments both significantly lower. The quarter swung to a net loss of $72.9 million versus net income of $11.4 million, reflecting restructuring, asset disposals, impairments and accelerated depreciation; adjusted net loss was $27.7 million and Adjusted EBITDA was $(18.0) million.
For full year 2025, revenue fell to $271.1 million from $452.7 million, and Aspen recorded a net loss of $389.6 million, including a $291.2 million impairment tied to the previously planned Statesboro plant; adjusted net loss was $40.5 million and Adjusted EBITDA was $2.9 million, down from $89.9 million. The company ended 2025 with $158.6 million in cash, generated $32.9 million of operating cash flow, expects about $37.6 million from a GM commercial settlement in Q1 2026, and signed a non-binding LOI to sell Statesboro assets. Aspen initiated a strategic review with Piper Sandler to evaluate options for its long-term competitive position and guided Q1 2026 revenue to $35–$40 million with a projected net loss of $20–$23 million and Adjusted EBITDA between $(10) million and $(13) million.
Needham Investment Management L.L.C., Needham Asset Management, LLC, and George A. Needham report a passive 5.3% ownership stake in Aspen Aerogels Inc. They collectively report beneficial ownership of 4,351,700 shares of Aspen Aerogels common stock, with shared voting and dispositive power over all reported shares and no sole authority.
All of the securities are directly owned by advisory clients of Needham Investment Management L.L.C., and no individual client is described as holding more than 5% of the common stock. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Aspen Aerogels.
Aspen Aerogels filed an amended insider ownership report for its CFO and Treasurer following an equity grant. On October 1, 2025, the officer acquired 10,273 restricted stock units (RSUs) of common stock at a price of $0 per unit, reflecting a compensation award rather than an open-market purchase.
Each RSU represents one share of common stock and vests in three equal installments: one-third on March 5, 2026, one-third on March 5, 2027, and the final third on March 5, 2028. After correcting prior figures, the filing states the officer beneficially owns 25,392 share-based interests, consisting of 4,608 shares of common stock and 20,784 RSUs. The amendment explains that an earlier report had omitted 10,511 RSUs that were granted before the October 1, 2025 transaction date.
Aspen Aerogels filed an amended insider ownership report for its CFO and Treasurer. The filing shows that the officer beneficially owns 15,119 shares of common stock, including 4,608 shares of common stock and 10,511 restricted stock units (RSUs). The RSUs were granted on March 8, 2023, March 5, 2024, and March 5, 2025, with various time-based vesting schedules extending through March 5, 2028. The amendment clarifies that these unvested RSUs had been inadvertently omitted from the reporting person’s original filing.